Alimera Sciences Inc. (ALIM)

0.87
NASDAQ : Health Technology
Prev Close 0.87
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.74 / 1.65
Avg Volume 165.00K
Exchange NASDAQ
Shares Outstanding 70.04M
Market Cap 60.23M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Appoints Mary T. Szela To Its Board Of Directors

Alimera Sciences Appoints Mary T. Szela To Its Board Of Directors
The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability
Alimera Sciences Terminates At-the-Market Offering Agreement

Alimera Sciences Terminates At-the-Market Offering Agreement

ATLANTA, June 4, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank...

Alimera Sciences To Present At The 8th Annual LD Micro Invitational Conference

Alimera Sciences Reports Fourth Quarter And Full Year 2017 Financial Results

Alimera Sciences Reports Fourth Quarter And Full Year 2017 Financial Results

Alimera Sciences To Present At The 38th Annual Cowen & Co. Health Care Conference

Alimera Sciences To Present At The 38th Annual Cowen & Co. Health Care Conference

Alimera Sciences To Report Fourth Quarter And Full Year 2017 Results On February 28, 2018

Alimera Sciences To Report Fourth Quarter And Full Year 2017 Results On February 28, 2018

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For ILUVIEN® Non-Infectious Posterior Uveitis Indication In Europe

Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For ILUVIEN® Non-Infectious Posterior Uveitis Indication In Europe

Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland

Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland

Alimera Sciences Announces Nine Iluvien® Data Sets To Be Presented At 2017 American Academy Of Ophthalmology

Alimera Sciences Announces Nine Iluvien® Data Sets To Be Presented At 2017 American Academy Of Ophthalmology

Alimera Sciences' CEO Dan Myers To Present During Ophthalmology Innovation Summit At American Academy Of Ophthalmology 2017

Alimera Sciences' CEO Dan Myers To Present During Ophthalmology Innovation Summit At American Academy Of Ophthalmology 2017

Alimera Sciences Reports Third Quarter 2017 Financial Results

Alimera Sciences Reports Third Quarter 2017 Financial Results

Alimera Sciences To Report Third Quarter 2017 Results November 1st, 2017

Alimera Sciences To Report Third Quarter 2017 Results November 1st, 2017

Alimera Sciences Announces Four Data Sets For ILUVIEN® To Be Presented At 2017 Retina Society's Annual Meeting

Alimera Sciences Announces Four Data Sets For ILUVIEN® To Be Presented At 2017 Retina Society's Annual Meeting

Alimera Sciences To Present At The Sidoti & Company Fall 2017 Conference

Alimera Sciences To Present At The Sidoti & Company Fall 2017 Conference

Alimera Sciences Announces ILUVIEN® Now Available In Ireland

Alimera Sciences Announces ILUVIEN® Now Available In Ireland

Weather Related Conditions Cancels Alimera Sciences Presentation At Rodman & Renshaw Global Investment Conference

Weather Related Conditions Cancels Alimera Sciences Presentation At Rodman & Renshaw Global Investment Conference

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences To Present At The 19th Annual Rodman & Renshaw Global Investment Conference

Alimera Sciences To Present At The 19th Annual Rodman & Renshaw Global Investment Conference

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

Alimera Sciences Announces Data To Be Presented At The 2017 Annual ASRS Meeting

Alimera Sciences Announces Data To Be Presented At The 2017 Annual ASRS Meeting

Alimera Sciences' CEO Dan Myers To Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit At ASRS, August 10, 2017

Alimera Sciences' CEO Dan Myers To Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit At ASRS, August 10, 2017

Alimera Sciences Reports Second Quarter 2017 Financial Results

Alimera Sciences Reports Second Quarter 2017 Financial Results

Alimera Sciences Announces Real-World Audit Data Supporting The Positive Benefits Of ILUVIEN® Treatment

Alimera Sciences Announces Real-World Audit Data Supporting The Positive Benefits Of ILUVIEN® Treatment

Alimera Sciences To Report Second Quarter 2017 Financial Results On August 2nd, 2017

Alimera Sciences To Report Second Quarter 2017 Financial Results On August 2nd, 2017

Positive Results Enable Alimera Sciences To Reduce Enrollment In ILUVIEN® Registry Safety Study In The U.K.

Positive Results Enable Alimera Sciences To Reduce Enrollment In ILUVIEN® Registry Safety Study In The U.K.

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Signs license agreement with pSivida for posterior uveitis in Europe, the Middle East and Africa

Alimera Sciences Reports First Quarter 2017 Financial Results

Load More
Quant Rating on 3:59 PM EDT 6/21/2018

D-

(Sell)

From Our Partners

Reimbursement for Alimera's Iluvien set in Spain; shares up 2%
SeekingAlpha

Alimera Sciences price target lowered to $2.50 from $5 at H.C. Wainwright
The Fly

Alimera Sciences, Inc. 2018 Q1 - Results - Earnings Call Slides
SeekingAlpha

Alimera Sciences misses by $0.05, misses on revenue
SeekingAlpha

FDA OKs AI software to detect diabetic retinopathy
SeekingAlpha

Key events next week - healthcare (continued #2)
SeekingAlpha

Alimera Sciences misses by $0.06, misses on revenue
SeekingAlpha

Notable earnings after Wednesday’s close
SeekingAlpha

Alimera's European application for expanded use of Iluvien under review
SeekingAlpha

Healthcare events next week
SeekingAlpha

CMS issues final list of therapies facing expiration of pass-through status for 2018
SeekingAlpha

Alimera Sciences, Inc. 2017 Q3 - Results - Earnings Call Slides
SeekingAlpha

Alimera Sciences misses by $0.03, misses on revenue
SeekingAlpha

Notable earnings after Wednesday’s close
SeekingAlpha

Alimera registers $100M mixed shelf offering
SeekingAlpha
TheStreet Quant Rating: D- (Sell)

Get the (ALIM)
Report Here

Free Reports

Watchlist

Trending
Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)
3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio
Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers